COMMERCE BUSINESS DAILY ISSUE OF JULY 28,2000 PSA#2652 National Cancer Institute, Research Contracts Branch, PCPSS, Executive
Plaza South, Room 635, Bethesda, Md 20892 A -- PHASE I CLINICAL STUDIES OF CHEMOPREVENTIVE AGENTS SOL
N01-CN-85080-70 DUE 101500 POC Theresa H.Shroff, Contracting Officer,
301-435-3796 WEB: N01-CN-85080-70 Phase I Clinical Studies of
Chemopreventive, http://rcb.nci.nih.gov/RFP.HTM. E-MAIL: Theresa H.
Shroff, ts144t@nih.gov. ELECTRONIC RFP ANNOUNCEMENT. POTENTIAL OFFERORS
WILL BE RESPONSIBLE FOR DOWNLOADING THIER OWN COPY OF THE SOLICITATION
AND AMENDMENTS. The Chemoprevention Branch of the Division of Cancer
Prevention (DCP), National Cancer Institute (NCI), National Institutes
of Health (NIH) is expanding the existing Master Agreement pool with
the objective of conducting phase I clinical trials to evaluate the
pharmacokinetics, pharmacology, and toxicology of chemopreventive
agents, as well as to evaluate the modulation of biological markers of
carcinogenesis. The application of biological markers to clinical
prevention trials carries great promise in relation to ultimate cancer
prevention. When cancer incidence reduction itself is used as an
endpoint in studies of this type, a very large number of subjects
tested for long durations is often required. The design of phase 1a
clinical trials will be small, single-dose, efficient studies that
determine the dose-response of a given chemopreventive agent on
pharmacokinetics,pharmacology, and toxicology. The second segment,
phabe 1b study, will involve a sequential, short-term (3-6 month),
dose-escalation trial (in some cases randomized, placebo-controlled,
and blinded) in a small group of subjects in which the endpoints will
be pharmacokinetics, pharmacology, toxicology, and exploration of the
modulation of quantifiable biological effects that are correlated with
cancer incidence reduction. The maximum tolerated dose and the minimum
effective dose will be determined. Master Agreements will be awarded to
all respondents whose technical proposal is considered acceptable. The
Master Agreement award is a non-monetary and is exclusively for the
purpose of compiling a pool of contractors who are pre-qualified to
perform services to perform specific Phase I studies. Each Master
Agreement holder will be eligible to compete for future contract awards
to carry out specific Phase I studies. Master Agreement holders
receiving a contract award will be selected through this pool, based on
technical merit and on budgetary considerations for specific tasks
involved. Any MA awarded as a result of this solicitation will be in
effect from the effective date to February 15, 2003. This solicitation
will be open for the duration of the existing MA pool with due date
for receipt of proposals of October 15 of each year. All responsible
sources meeting these criteria are encouraged to submit a proposal and
a sample requirement to be considered by the NCI. ALL MASTER AGREEMENT
HOLDERS ALREADY IN THE EXISTING MASTER AGREEMENT POOL NEED NOT RESPOND
TO THIS ANNOUNCEMENT. The RFP may be accessed through the Research
Contracts Branch Home Page by using the following Internet address:
http://rcb.nci.nih.gov/RFP.HTM. It is the offerors responsibility to
monitor the above Internet site for the release of this solicitation
and amendments, if any. POTENTIAL OFFERORS WILL BE RESPONSIBLE FOR
DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND AMENDMENTS. Point of
contact: Theresa H. Shroff, Contracting Officer, NCI, RCB, PCPSS; 6120
Executive Boulevard, Executive Plaza South, Room 635, Rockville, MD
20852; Phone: 301-435-3796; FAX: 301-402-8579; Electronic mail address:
ts144t@nih.gov. All requests should reference the RFP No.
N01-CN-85080-70. No collect calls will be accepted. Posted 07/26/00
(W-SN478842). (0208) Loren Data Corp. http://www.ld.com (SYN# 0007 20000728\A-0007.SOL)
| A - Research and Development Index
|
Issue Index |
Created on July 26, 2000 by Loren Data Corp. --
info@ld.com
|
|
|